Full results of repurposed cancer drug trial highlight potential benefits
Previous top line results indicated that, while safe, Nilotinib failed to show benefit. The full results now show that there may be some potential benefits.
8 remarkable things we achieved together in 2019, and recent years
2019 was another exciting year of progress. Here are 8 of the highlights, and 8 ways you can still get involved.
New international initiative to investigate the genetics of Parkinson’s
As part of the Aligning Science Across Parkinson’s (ASAP) initiative, an ambitious global five-year programme was announced today to understand the genetic root of Parkinson’s.
Results of phase 2 nilotinib study show no benefit
Results have been shared from the US-based phase 2 clinical trial of nilotinib in people with moderate to advanced Parkinson's.
While safe and tolerable, the repurposed drug did not appear to have beneficial effects.
Progress in gene therapy treatment for Parkinson's
Researchers, funded by Parkinson's UK, have produced positive results in mice for a gene therapy treatment that directly targets the production of the alpha-synuclein protein.
Could sleep boost waste disposal in the brain and prevent Parkinson’s?
Alongside Alzheimer’s Research UK, we’re funding new research that will investigate whether boosting the brain’s self-cleaning system could be the key to new treatments.
Caution when looking at cell recycling in Parkinson’s
Researchers at the Oxford Parkinson’s Disease Centre have shown that cell recycling in Parkinson’s may play a more complex role than previously thought. These new results have been published in the journal of Cell Reports.
Revolutionary research advocate Ken Bowler dies aged 76
The Parkinson’s community in Scotland, and beyond, has lost one of its giants with the passing of Professor Ken Bowler. Ken revolutionised the relationship between researchers and people living with Parkinson’s.
New research: Ex-footballers more likely to get Parkinson's
Former professional footballers are more likely to die with a neurodegenerative condition such as dementia or Parkinson's than the general population, according to new research.